Product Description
For Chronic Obstructive Pulmonary Disease (COPD). a new bronchodilator indicated for treatment of chronic obstructive pulmonary disease (COPD). (Sourced from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002974-20/BE; https://pubmed.ncbi.nlm.nih.gov/16030078/)
Mechanisms of Action: LAM Antagonist,mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Cyprus | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Jordan | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Philippines | Poland | Romania | Russia | South Africa | Spain | Sri Lanka | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Dyspnea|Chronic Obstructive Pulmonary Disease|Asthma|Respiratory Tract Infections|Bronchitis, Chronic|Emphysema|Respiratory Aspiration
Phase 3: Chronic Obstructive Pulmonary Disease|Asthma|Respiratory Aspiration|Cystic Fibrosis|Dyspnea
Phase 2: Chronic Obstructive Pulmonary Disease|Asthma|Respiratory Aspiration|Non-Small-Cell Lung Cancer|Dyspnea|Small Cell Lung Cancer
Phase 1: Healthy Volunteers|Chronic Obstructive Pulmonary Disease|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT06679465 | P4 |
Not yet recruiting |
Asthma |
2027-01-01 |
|
| TRITON | N/A |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2025-03-01 |
|
| GiresunU-PULMONOLOGY-HB-01 | N/A |
Completed |
Chronic Obstructive Pulmonary Disease|Glaucoma, Angle-Closure |
2024-03-30 |
|
| PIFR-2 | P4 |
Completed |
Respiratory Aspiration|Chronic Obstructive Pulmonary Disease |
2023-11-13 |